<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00136396</url>
  </required_header>
  <id_info>
    <org_study_id>03-120</org_study_id>
    <nct_id>NCT00136396</nct_id>
  </id_info>
  <brief_title>Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease</brief_title>
  <official_title>An Open Label, Phase I/II Trial of Rituximab Therapy for Steroid-Refractory Chronic Graft vs. Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if rituximab is a safe and effective therapy for&#xD;
      steroid-refractory chronic graft versus host disease (GVHD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive rituximab intravenously one time per week for four consecutive weeks.&#xD;
      Once therapy is completed, the patient will have weekly visits with their physician for four&#xD;
      more weeks, at which they will complete a simple questionnaire designed to evaluate the&#xD;
      severity of chronic graft versus host disease.&#xD;
&#xD;
      At the end of the eighth week on the study (4 weeks of study treatment and 4 weeks of&#xD;
      observation), patients will be evaluated to determine whether their chronic graft versus host&#xD;
      disease (GVHD) has resolved.&#xD;
&#xD;
      If chronic graft versus host disease has resolved entirely, the patient will be monitored for&#xD;
      the remainder of the year.&#xD;
&#xD;
      If after the initial eight weeks on the study the patient still has symptoms or signs of&#xD;
      GVHD, they may receive a second four week study treatment.&#xD;
&#xD;
      If the patients' chronic GVHD reappears after receiving either one or two courses of&#xD;
      rituximab, a third and final four week course of medication can be given provided it has been&#xD;
      at least eight weeks since the last dose.&#xD;
&#xD;
      Blood tests will be performed at the beginning of the study, after 8 weeks on the study,&#xD;
      after 16 weeks on the study and at the end of 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety and efficacy of up to three four week courses of rituximab in steroid-refractory chronic GVHD</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the effects of rituximab therapy on quality of life of patients with steroid-refractory GVHD</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Graft vs Host Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given once weekly for 4 weeks followed by a 4 week observation therapy.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recipients of matched related, matched unrelated, or mismatched stem cell&#xD;
             transplantation&#xD;
&#xD;
          -  At least 180 days since allogeneic stem cell transplantation procedure&#xD;
&#xD;
          -  Patients must have steroid-refractory chronic GVHD, defined as having persistent signs&#xD;
             and symptoms despite the use of prednisone&#xD;
&#xD;
          -  Stable dose of corticosteroids for 4 weeks prior to enrollment&#xD;
&#xD;
          -  Adequate bone marrow function: absolute neutrophil count (ANC) &gt; 500/mm; platelets &gt;&#xD;
             20,000 ul&#xD;
&#xD;
          -  Adequate renal function: creatinine &lt; 3.0 mg/dl&#xD;
&#xD;
          -  Adequate hepatic function: bilirubin &lt; 3.0 mg/dl; AST &lt; 90 IU&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prednisone requirement greater than 2 mg/kg/day or equivalent&#xD;
&#xD;
          -  Known life-threatening sensitivity to rituximab or other anti-B cell antibody.&#xD;
&#xD;
          -  Prior exposure to any new immunosuppressive medication in the preceding 4 weeks prior&#xD;
             to enrollment.&#xD;
&#xD;
          -  Active, uncontrolled infection&#xD;
&#xD;
          -  Evidence of natural exposure to hepatitis B or C.&#xD;
&#xD;
          -  Active malignant disease relapse&#xD;
&#xD;
          -  Donor lymphocyte infusion within the preceding 100 days.&#xD;
&#xD;
          -  Life expectancy of less than 3 months.&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Evidence of HIV seropositivity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corey S. Cutler, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>August 26, 2005</study_first_submitted>
  <study_first_submitted_qc>August 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <last_update_submitted>June 10, 2013</last_update_submitted>
  <last_update_submitted_qc>June 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Corey S. Cutler, MD, MPH</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Steroid-refractory Chronic Graft vs. Host Disease</keyword>
  <keyword>Chronic Graft vs. Host Disease</keyword>
  <keyword>GVHD</keyword>
  <keyword>steroid-refractory</keyword>
  <keyword>rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

